Vimarsana
Biggest News Aggregation in the World

Page 3 - Advanced Prostate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Prostate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Prostate Today - Breaking & Trending Today

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 YOUNG INVESTIGATOR AWARDS TOTALING $7.2 MILLION FOR PROSTATE CANCER RESEARCH - Vimarsana News

THE PROSTATE CANCER FOUNDATION ANNOUNCES 2022 YOUNG INVESTIGATOR AWARDS TOTALING $7.2 MILLION FOR PROSTATE CANCER RESEARCH

/PRNewswire/ -- The Prostate Cancer Foundation (PCF) today announced the Class of 2022 Young Investigator Award recipients totaling $7.2 million in funding for...

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza granted FDA priority review for PROpel - Vimarsana News

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza granted FDA priority review for PROpel

Investegate announcements from AstraZeneca PLC, Lynparza granted FDA priority review for PROpel

Global Cancer Therapies Market Report 2022: Market to Reach $209.2 Billion by 2026 - Industry Focuses on New Approaches to Treat Cancer - Vimarsana News

Global Cancer Therapies Market Report 2022: Market to Reach $209.2 Billion by 2026 - Industry Focuses on New Approaches to Treat Cancer

/PRNewswire/ -- The "Cancer Therapies - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Cancer...

Global Cancer Therapies Market Report 2022: Market to Reach $209.2 Billion by 2026 - Industry Focuses on New Approaches to Treat Cancer - Vimarsana News

Global Cancer Therapies Market Report 2022: Market to Reach $209.2 Billion by 2026 - Industry Focuses on New Approaches to Treat Cancer

/PRNewswire/ -- The "Cancer Therapies - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global Cancer...

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence - Vimarsana News

PROpel Phase III trial positive results of Lynparza plus abiraterone in 1st-line metastatic castration-resistant prostate cancer published in New England Journal of Medicine Evidence

Results from the PROpel Phase III trial showed that AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone significantly improved radiographic progression-free survival (rPFS) versus abiraterone alone as a 1st-line treatment for patients with metastatic castration-resistant prostate cancer ...